Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a biopharmaceutical company that develops drug candidates to be used in the treatment of central nervous system (CNS) disorders. Theranexus' unique, patented technology is aimed at increasing the efficacy of CNS drugs that have already been approved and are available on the market.

Theranexus' technology is protected, unique, scalable and versatile, and used to generate high value-added proprietary drug candidates for different conditions, while reducing time-to-market and market entry costs and risks in comparison with standard drug development processes.



THERANEXUS provides 2018 full-year results and update on activities

17/04/2019
Download PDF File (416 Ko)

THERANEXUS announces research collaboration with IRISA using artificial intelligence technologies to enhance therapeutic targeting of neuroglial interactions

09/04/2019
Download PDF File (376 Ko)

THERANEXUS to present new scientific data on drug candidate THN201 at AD/PD 2019, the 14th conference on Alzheimer's and Parkinson's diseases

26/03/2019
Download PDF File (377 Ko)

THERANEXUS announces preliminary results of phase II trial of THN102 on narcolepsy patients

27/02/2019
Download PDF File (296 Ko)

THERANEXUS reports cash position as of 31 December 2018 and provides update on current status of activities

13/02/2019
Download PDF File (395 Ko)

December, 2019 : CF&B Midcap Event, Geneva (exact date to be confirmed)

October 14 & 15, 2019 : CF&B European MidCap Event, Paris

September 20, 2019 : CF&B Midcap Event, Amsterdam

June 18 & 19, 2019 : CF&B Spring European Midcap, Paris 

May 14 & 15, 2019 : Large & MidCap Event (Midcap partners), Paris